Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Nov 2013 07:00 AM
RNS
?5 million Loan Facility from Lead Shareholder
19 Nov 2013 07:00 AM
RNS
Interim Management Statement
17 Oct 2013 07:00 AM
RNS
Agreement to Resume Clinical Trials
19 Sep 2013 07:00 AM
RNS
Director/PDMR Shareholding
17 Sep 2013 01:06 PM
RNS
Block Listing Return
12 Sep 2013 11:18 AM
RNS
Oxford BioMedica plc Director's Share Purchase
11 Sep 2013 01:01 PM
RNS
Oxford BioMedica Wins Significant Funding
06 Sep 2013 04:40 PM
RNS
Second Price Monitoring Extn
06 Sep 2013 04:35 PM
RNS
Price Monitoring Extension
29 Aug 2013 04:08 PM
RNS
TR1 Form
29 Aug 2013 07:00 AM
RNS
Interim Results 2013
28 Aug 2013 07:00 AM
RNS
US$1 million Milestone Payment from Pfizer
14 Aug 2013 01:00 PM
RNS
Announced as Funding Competition Winner
29 Jul 2013 07:00 AM
RNS
Publication of TroVax Phase II Analyses
23 Jul 2013 07:00 AM
RNS
Notice of Interim Results
16 Jul 2013 11:20 AM
RNS
Director/PDMR Shareholding
01 Jul 2013 07:00 AM
RNS
Update on Glaucoma-GT
28 Jun 2013 07:00 AM
RNS
Total Voting Rights
20 Jun 2013 11:15 AM
RNS
Director/PDMR Shareholding
19 Jun 2013 11:00 AM
RNS
TR-1: Notification of Major Interest in Shares
12 Jun 2013 07:00 AM
RNS
Directors' Interests in Share Options
10 Jun 2013 12:59 PM
RNS
Director/PDMR Shareholding
10 Jun 2013 12:59 PM
RNS
TR-1: Notification of Major Interest in Shares
10 Jun 2013 07:00 AM
RNS
Director's Share Purchase
06 Jun 2013 11:45 AM
RNS
Result of AGM
06 Jun 2013 07:00 AM
RNS
Change of Adviser and Broker
06 Jun 2013 07:00 AM
RNS
Management and Board change
05 Jun 2013 10:43 AM
RNS
TR-1: Notification of Major Interest in Shares
03 Jun 2013 07:00 AM
RNS
Clinical Trial Update
24 May 2013 10:00 AM
RNS
BLOCK LISTING RETURN
16 May 2013 07:00 AM
RNS
Interim Management Statement
09 May 2013 09:00 AM
RNS
Update from ARVO 2013
03 May 2013 02:00 PM
RNS
Holding(s) in Company
03 May 2013 02:00 PM
RNS
Director/PDMR Shareholding
01 May 2013 07:03 AM
RNS
Collaboration with Novartis
17 Apr 2013 01:00 PM
RNS
2012 ANNUAL REPORT & ACCOUNTS & AGM NOTIFICATION
07 Mar 2013 07:00 AM
RNS
Initiation of PII Collaborative Study for TroVax
27 Feb 2013 07:00 AM
RNS
Preliminary Results
25 Jan 2013 04:40 PM
RNS
Second Price Monitoring Extn
25 Jan 2013 04:35 PM
RNS
Price Monitoring Extension
23 Jan 2013 07:00 AM
RNS
Notice of Preliminary Results
29 Nov 2012 07:00 AM
RNS
Exercise of Option by ImaginAb
28 Nov 2012 07:00 AM
RNS
Block Listing Return
20 Nov 2012 07:00 AM
RNS
Ocular Clinical Programme Update
14 Nov 2012 07:00 AM
RNS
Interim Management Statement
09 Nov 2012 07:00 AM
RNS
Issue of Key US Patent
10 Oct 2012 07:00 AM
RNS
Update on TroVax (R) Development Strategy
03 Oct 2012 07:00 AM
RNS
Board Change
27 Sep 2012 08:00 AM
RNS
Collaboration With Immune Design Corp.
26 Sep 2012 04:40 PM
RNS
Second Price Monitoring Extn

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100